MedReleaf Announces $100 Million Deal

MedReleaf Corp. (MEDFF) stock popped over 7% on the OTC Marketplace following the announcement of a $100 million bought deal. Shares jumped over 7% to lately trade at $23.66. This is near the high of its 52-week range of $24.99.

The company announced that it has entered into an agreement with Canaccord Genuity Corp. and GMP Securities L.P.  to purchase, on a bought deal basis  3,800,000 units of the company at a price of $26.50 per share for aggregate gross proceeds of $100.7 million. The deal is expected close on or around January 31, 2018.

According to the company statement, MedReleaf plans on using the net proceeds to finance the acquisition and/or construction of additional cannabis production and manufacturing facilities in Canada as well as in other jurisdictions with federal legal markets.

Each unit will consist of one common share and one-half of one common share purchase warrant of MedReleaf. Each warrant will be exercisable to acquire one common share of the Company for a period of two years following the closing date at an exercise price of $34.50. In the event that the volume weighted average trading price exceeds $51.75 for ten consecutive days, MedReleaf will have the right to accelerate the expiry date of the warrants upon not less than fifteen trading days’ notice.

MedReleaf is the first and only ICH-GMP and ISO 9001 certified cannabis producer in North America. MedReleaf is an R&D-driven company dedicated to patient care, scientific innovation, research and advancing the understanding of the therapeutic benefits of cannabis. Sourced from around the world and carefully cultivated in one of two state of the art facilities in Ontario, MedReleaf delivers a variety of premium products to patients seeking safe, consistent and effective medical cannabis.

Cannabis stocks tumbled last week after Attorney General Jeff Sessions rescinded the Cole Memorandum which gave a level of protection to the cannabis companies in U.S. The Cole Memo also made Canadian companies feel a little more secure when dealing with the U.S. So far there has been little response with regards to immediately arresting companies engaged in the cannabis industry. Instead, states, where marijuana has been legalized, have vowed to fight back.

Debra Borchardt

Debra Borchardt is the CEO, Co-Founder, and Editor-In-Chief of GMR. She has covered the cannabis industry for several years at Forbes, Seeking Alpha and TheStreet. Prior to becoming a financial journalist, Debra was a Vice President at Bear Stearns where she held a Series 7 and Registered Investment Advisor license. Debra has a Masters degree in Business Journalism from New York University.

Leave a Reply

Your email address will not be published. Required fields are marked *

Don't Miss This Week's Groundbreaking News

Join the thousands of subscribers who stay informed with GMR's exclusive news briefs delivered directly to your inbox every Friday afternoon.

We respect your privacy. See our privacy policy.

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


Recent Tweets

@GreenMarketRpt – 11 hours

New Report from ⁦@headset_io⁩ Says Medical Cannabis Consumers Spend More. New story from ⁦@julsaitch⁩

@GreenMarketRpt – 12 hours

Yowza. Be careful when investing in crowdfunding deals. SEC files complaint against CEO and others for…

Back to Top